The Form 4 filing, an SEC report of insider stock activity, was filed on November 9, 2026. The reported sales took place from November 5 through November 9, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-05 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 129,604 |
| Price | $35.71 |
| Total Transaction Value | $4,628,500.08 |
| Insider | |
| Ticker Symbol | PGNY |
| Company | Progyny, Inc. |
| Insider Name | Anevski Peter |
| Insider Title | CHIEF EXECUTIVE OFFICER |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 797,572 |
| Position Size Change | 13.98% |
| Filing | |
| Filing Date | 2026-11-09 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Progyny (PGNY) shares under SEC transaction code S. The report covers two sale transactions, with a link to a separate share acquisition explained below.
What was the average price of the transaction?
The average sale price was $35.71 per share, rounded to the nearest cent. This average covers the two reported sales.
How did this transaction affect the insider's holdings?
Peter Anevski sold 129,604 shares and reported owning 797,572 shares afterward. The shares sold were 13.98% of his reported shares owned before the sales.
What's the total transaction value?
The two sales had a total value of $4,628,500.08, rounded to the nearest cent.
Are there any special circumstances around this transaction?
Yes. The sales were identified as linked to a code M exercise or conversion. An exercise uses a stock right to acquire shares; a conversion exchanges one type of security for another.
The link is based on matching share counts within the same filing. Details of the matching acquisition and the filing's footnotes are unavailable here. The match alone does not confirm matching dates, share types or accounts, or that the exact shares received were sold. It also does not establish a tax purpose or a sale on the day the shares were acquired.
For research purposes only; not investment advice.